Clinical Trials Logo

Filter by:
NCT ID: NCT04133324 Recruiting - Anastomotic Leak Clinical Trials

C-protein Reactive for the Detection of Anastomotic Leakage After Surgery for Digestive Cancer

Start date: April 1, 2018
Phase:
Study type: Observational

The aim of this study is to investigate the diagnostic accuracy of the C Protein Reactive (CRP) for the detection of Anastomotic leakage after surgery for digestive cancer. The standard protocol in our unit is to measure the CRP on the second and fourth postoperative day. The main aim of the study is to investigate the diagnostic accuracy of the ratio CRP on the fourth postoperative day on CRP on the second postoperative day (CRP_D4/CRP_D2). Secondary outcomes are the diagnosis accuracy of the CRP_D4 and CRP_D2.

NCT ID: NCT04130568 Completed - Clinical trials for Learning Organization

Translation and Adaptation of Learning Organisation Survey for French Speaking Countries

Start date: August 1, 2019
Phase:
Study type: Observational

Learning organizations need a diagnostic tool that allows them to assess how well their team, department or the entire institution is performing, that allow them identify areas of improvement. In turn, having that tool in your own language (in this case French) and adapted to your own context, gives reliability and ease of application. Health organizations are starting to use more and more tools like this that allow them to improve their learning capabilities and therefore their performance. Aim : described the translation of Garvin's et al. Learning Organization Survey into French to evaluate french speaking health organizations.

NCT ID: NCT04128657 Completed - Clinical trials for Rectal Cancer Patients

Validation of the Moroccan Arabic Version of the Low Anterior Resection Syndrome (LARS) and Wexner Score of Continence Among Rectal Cancer Patients

MA_LARSWEX
Start date: January 1, 2019
Phase:
Study type: Observational

In the past decade, colorectal cancer management improved considerably with total mesorectal excision as well as the multidisciplinary management relying on neoadjuvant radiochemotherapy. This forward leap is currently responsible for an increase in the survivorship of colorectal cancer patients to more than 50% at 5 years. Additively the surgical approach is now more inclined towards sphincter preserving procedures, which allows the conservation of body image but can have negative bowel function repercussions consisting of urgency and incontinence ; all these terms encompassed in the low anterior resection syndrome. In the light of these findings many studies developed assessment tools in order to objectively measure this functional alteration among which are the low anterior resection syndrome questionnaire (LARS) and the WEXNER score. These tools designed to assess bowel function after sphincter-preserving surgery are now translated and validated into various languages and used in different countries. The LARS score relies on the frequency of the symptoms and allows the categorization of patients into 3 groups: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points). It assesses the frequency of emptying, incontinence ( liquid, gas ), and other symptoms such as urgency and incomplete voiding. On the other hand, the WEXNER score relies on the examination of the frequency of three types of fecal incontinence (solid, liquid, and gas) and their consequences (pad wearing and lifestyle alteration) with frequency options ranging from never (score 0) through to always (meaning at least once per day; score 4). The score ranges from 0 (perfect continence) to 20 (complete incontinence). The aim of our study is to adapt and validate the LARS and WEXNER score to the moroccan arabic dialect.

NCT ID: NCT04035005 Recruiting - Clinical trials for Multiple Sclerosis, Primary Progressive

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

O'HAND
Start date: August 12, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression. This study will consist of the following phases: screening, double-blind treatment, follow-up 1 (FU1), an optional open-label extension (OLE), follow-up 2 (FU2), and B-cell monitoring (BCM).

NCT ID: NCT04000802 Completed - Decision Making Clinical Trials

Evaluation of the Decision-making During Multidisciplinary Meetings for Digestive Cancers

Start date: May 23, 2019
Phase:
Study type: Observational

Nowadays, the recommended approach for decision-making for oncology patients is based on multidisciplinary meetings (MDT). However, the quality of decision-making during MDT depends on other factors such as the quality of presentation of clinical cases, the degree of participation of different specialists. In this study, the investigators will evaluate the decision-making during digestive oncology MDT using the validated "Metric Of Decision-Making" tool (MDT-MODe), in the national institute of oncology (Rabat, Morocco).

NCT ID: NCT03981081 Recruiting - Clinical trials for Mechanical Ventilation

Prednisone Reduction in ICU Patients With COPD Exacerbation

EoPred-ICU
Start date: April 2, 2019
Phase: Phase 4
Study type: Interventional

The aim of this multicenter, investigator-initiated, prospective, randomized, open-label, non-inferiority study is to evaluate a prednisone prescribing strategy, guided by eosinophil blood count compared to the standard (systematic) administration of corticosteroids, in patients with COPD exacerbation requiring ventilatory support. Patients fulfilling inclusion criteria and consenting to participate in the study, will be randomized through a random table generated electronically, to eosinophil-guided group or to control group. In the eosinophil-guided group, prednisone (1mg/kg/day for up to 5 days or during the hospital stay if less than 5 days) is administered only if the eosinophil count is >2%. If blood eosinophil count is ≤2%, no corticosteroids are given. In the control group: a treatment based on prednisone at a daily dose of 1 mg/kg will be routinely administered for a maximum of 5 days, or during the hospital stay, if it is less than 5 days. Corticosteroid treatment is taken in the morning in patients with NIV, and through the gastric tube in intubated patients. The hypothesis tested is a non-inferiority of the "eosinophil-guided strategy" compared to the standard strategy, with less exposure to corticosteroids. The primary endpoint is the proportion of unventilated patients at day 6 which is set to 50% in the control group. A pre-specified difference <10% would be a non-inferiority margin. Secondary endpoints are: Number of ICU days alive without ventilatory support within 28 days after recruitment, length of stay in intensive care Unit, the intubation rate in patients initially under NIV, Mortality in the ICU, Hospital mortality. Safety: New onset of diabetes or worsening of diabetes requiring the start or the increase in insulin therapy, Upper gastrointestinal bleeding (2 g drop of Hb requiring blood transfusion or fibroscopy), Uncontrolled hypertensive crisis requiring the introduction of new antihypertensives, ICU-acquired neuromyopathy, Nosocomial infection, Relapse rate / recurrence defined respectively by the rate of a new hospital consultation and/or admission in the week or the month following index hospitalization. Sample size calculation: In a non-inferiority study, with an incidence of the event (no ventilation at D6) of 50% in the control group ( with 10% of acceptable difference for non-inferiority), a power of 80% and alpha error <0.05, it would take 86 patients per arm by anticipating 2% of lost sight.

NCT ID: NCT03967067 Completed - Liver Diseases Clinical Trials

Risk Factors for Major Complications After Liver Resection

Start date: January 1, 2010
Phase:
Study type: Observational

The aim of this study is to determine the risk factors for major complications following liver resection in the setting of a general surgery-teaching department in Morocco, North Africa

NCT ID: NCT03727620 Completed - Clinical trials for Aggressive Periodontitis

Doxycycline in the Treatment of Aggressive Periodontitis

Start date: January 6, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the study was to compare the clinical effects of systemic use of doxycycline to amoxicillin plus metronidazole as adjunctive treatment in nonsurgical debridement of aggressive periodontitis (AgP). Twenty four patients with aggressive periodontitis were enrolled in this clinical study. They all received oral hygiene instruction and full-mouth nonsurgical debridement using manual instruments. The test group received as adjunctive antibiotic treatment 200 mg of doxycycline the first day followed by 100 mg per day during 14 days. The control group received 500 of amoxicillin and 250 of metronidazole, three times a day for 7 days.

NCT ID: NCT03681600 Terminated - Surgery Clinical Trials

Observatory of the Quality of Surgical Procedures for Digestive Cancers

Obchir
Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

Surgery for digestive cancers is managed according to quality standards, validated by the scientific community. Despite the diffusion of these standards through the benchmarks of good practice, the results of the surgery remain disparate. In many countries, this "inequality of opportunity" has justified the establishment of quality assurance systems to measure the results of surgery for one or more localizations of digestive cancer. These surgical audit experiments have shown a positive, rapid and cost-effective impact on complication rates, recurrence rates and overall survival even in the absence of interventional measures. The data collected also helped to improve the management of subgroups of patients usually excluded from clinical trials. In Morocco, the National Cancer Prevention and Control Plan provides for the establishment of a quality assurance system with the introduction of a system for monitoring and evaluating the care of patients. This pilot project is part of this framework, for the group of patients who are candidates for surgery for digestive cancers.

NCT ID: NCT03618914 Completed - Inflammation Clinical Trials

Anemia and Inflammation

Start date: September 15, 2017
Phase:
Study type: Observational

During inflammation hepcidin concentrations are increased, leading to a decrease in iron absorption. In iron deficiency anemia hepcidin is suppressed due to the activation of erythropoiesis. Whether inflammation or anemia has the stronger effect on hepcidin is uncertain.